Human leukocyte antigen-A genotype as a predictor of cytomegalovirus-pp65 antigenemia and cytomegalovirus disease in solid-organ transplant recipients

详细信息    查看全文

• 作者：Reham Khalifa^a ; ; Ayman Asaad^a ; Maha Hussein^b
• 关键词：Cytomegalovirus ; CMVpp65 antigenemia ; HLA alleles ; Transplantation
• 刊名：Egyptian Journal of Medical Human Genetics
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：17
• 期：4
• 页码：345-352
• 全文大小：683 K

文摘

Cytomegalovirus (CMV) infection is one of the most common and severe infections during the post-transplantation period. It threatens the survival of patients and the function of the transplanted organ.

Aim of the study

To screen for CMV infection among solid organ transplantation patients using monitoring of CMV phosphoprotein 65 (CMVpp65) antigenemia and to detect if CMV infection and disease were associated with certain human leukocyte antigen (HLA)-A locus genotypes among the studied group.

Subjects and methods

Thirty solid organ transplantation patients were included for post-transplantation follow up for symptoms and signs suggestive of CMV disease upto one year. Regular screening for CMV infection was done through CMVpp65 antigenemia detection by the immunofluorescence technique. In addition, HLA-A genotype was determined for all patients using the line probe assay.

Results

The present study showed that 9 out of 30 patients (30%) were positive for CMVpp65 antigenemia. The detected HLA-A alleles were HLA-A*01(no. = 16), HLA-A*02(no. = 11), HLA-A*11(no. = 5), HLA-A*19(no. = 1), HLA-A*24(no. = 4), HLA-A*29(no. = 1), HLA-A*30(no. = 16), HLA-A*92(no. = 4). Among the studied cases, 40% showed HLA-A*01–30 type. There was a significant difference (P = 0.05) among detected HLA types as regards CMVpp65 antigenemia, with HLA-A*02_11 representing 33.3% of CMVpp65 positive patients and HLA-A*01_30 representing 57.1% of CMVpp65 negative patients.

Conclusion

Certain HLA alleles may have either a protective or predisposing role in CMV reactivation. Thus, HLA typing might be helpful in estimating the risk of CMV disease during the post-transplantation period and designing individualized therapy as regards the choice between preemptive and prophylactic CMV therapy.